More recently a PTH related protein (PTHrP) analog was also approved for the treatment of osteoporosis under the name abaloparatide.(1) It is well accepted that intermittent PTH (iPTH) therapy is anabolic for bone, whereas continuous PTH exposure is catabolic. Here, PTH is linked to osteoporosis.